These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 34830750)
1. Molecular Response to Combined Molecular- and External Radiotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC). Rassamegevanon T; Feindt L; Koi L; Müller J; Freudenberg R; Löck S; Sihver W; Çevik E; Kühn AC; von Neubeck C; Linge A; Pietzsch HJ; Kotzerke J; Baumann M; Krause M; Dietrich A Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830750 [TBL] [Abstract][Full Text] [Related]
2. Inactivation of HNSCC cells by 90Y-labeled cetuximab strictly depends on the number of induced DNA double-strand breaks. Saker J; Kriegs M; Zenker M; Heldt JM; Eke I; Pietzsch HJ; Grénman R; Cordes N; Petersen C; Baumann M; Steinbach J; Dikomey E; Kasten-Pisula U J Nucl Med; 2013 Mar; 54(3):416-23. PubMed ID: 23345302 [TBL] [Abstract][Full Text] [Related]
3. Cytotoxic properties of radionuclide-conjugated Cetuximab without and in combination with external irradiation in head and neck cancer cells in vitro. Eke I; Ingargiola M; Förster C; Kunz-Schughart LA; Baumann M; Runge R; Freudenberg R; Kotzerke J; Heldt JM; Pietzsch HJ; Steinbach J; Cordes N Int J Radiat Biol; 2014 Aug; 90(8):678-86. PubMed ID: 24597752 [TBL] [Abstract][Full Text] [Related]
4. EGFR-inhibition enhances apoptosis in irradiated human head and neck xenograft tumors independent of effects on DNA repair. Stegeman H; Span PN; Cockx SC; Peters JP; Rijken PF; van der Kogel AJ; Kaanders JH; Bussink J Radiat Res; 2013 Oct; 180(4):414-21. PubMed ID: 24059677 [TBL] [Abstract][Full Text] [Related]
5. Chloroquine reverses chemoresistance via upregulation of p21 Hwang JR; Kim WY; Cho YJ; Ryu JY; Choi JJ; Jeong SY; Kim MS; Kim JH; Paik ES; Lee YY; Han HD; Lee JW Cell Death Dis; 2020 Dec; 11(12):1034. PubMed ID: 33277461 [TBL] [Abstract][Full Text] [Related]
6. Cellular and molecular properties of (90)Y-labeled cetuximab in combination with radiotherapy on human tumor cells in vitro. Saki M; Toulany M; Sihver W; Zenker M; Heldt JM; Mosch B; Pietzsch HJ; Baumann M; Steinbach J; Rodemann HP Strahlenther Onkol; 2012 Sep; 188(9):823-32. PubMed ID: 22875052 [TBL] [Abstract][Full Text] [Related]
7. Potential of a Cetuximab-based radioimmunotherapy combined with external irradiation manifests in a 3-D cell assay. Ingargiola M; Runge R; Heldt JM; Freudenberg R; Steinbach J; Cordes N; Baumann M; Kotzerke J; Brockhoff G; Kunz-Schughart LA Int J Cancer; 2014 Aug; 135(4):968-80. PubMed ID: 24615356 [TBL] [Abstract][Full Text] [Related]
8. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models. Frederick BA; Gupta R; Atilano-Roque A; Su TT; Raben D Radiat Res; 2020 Nov; 194(5):519-531. PubMed ID: 32936912 [TBL] [Abstract][Full Text] [Related]
9. Early response monitoring with 18F-FDG PET and cetuximab-F(ab')2-SPECT after radiotherapy of human head and neck squamous cell carcinomas in a mouse model. van Dijk LK; Boerman OC; Franssen GM; Lok J; Kaanders JH; Bussink J J Nucl Med; 2014 Oct; 55(10):1665-70. PubMed ID: 25236350 [TBL] [Abstract][Full Text] [Related]
10. Radiotherapy enhances uptake and efficacy of Dietrich A; Andreeff M; Koi L; Bergmann R; Schubert M; Schreiner L; Löck S; Sihver W; Freudenberg R; Hering S; Pietzsch HJ; Steinbach J; Kotzerke J; Baumann M; Krause M Radiother Oncol; 2021 Feb; 155():285-292. PubMed ID: 33227356 [TBL] [Abstract][Full Text] [Related]
11. EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation. Alsahafi EN; Thavaraj S; Sarvestani N; Novoplansky O; Elkabets M; Ayaz B; Tavassoli M; Legends MF Cancer Lett; 2021 Feb; 498():80-97. PubMed ID: 33137407 [TBL] [Abstract][Full Text] [Related]
12. Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances Zeng L; Beggs RR; Cooper TS; Weaver AN; Yang ES Mol Cancer Ther; 2017 Apr; 16(4):591-600. PubMed ID: 28138028 [TBL] [Abstract][Full Text] [Related]
13. Aberrant p21(CIP1/WAF1) protein accumulation in head-and-neck cancer. Erber R; Klein W; Andl T; Enders C; Born AI; Conradt C; Bartek J; Bosch FX Int J Cancer; 1997 Aug; 74(4):383-9. PubMed ID: 9291426 [TBL] [Abstract][Full Text] [Related]
14. EGF-dependent induction of BCL-xL and p21CIP1/WAF1 is highly variable in HNSCC cells--implications for EGFR-targeted therapies. Rüddel J; Wennekes VE; Meissner W; Werner JA; Mandic R Anticancer Res; 2010 Nov; 30(11):4579-85. PubMed ID: 21115909 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit. Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701 [TBL] [Abstract][Full Text] [Related]
16. EGFR-amplification plus gene expression profiling predicts response to combined radiotherapy with EGFR-inhibition: A preclinical trial in 10 HNSCC-tumour-xenograft models. Koi L; Löck S; Linge A; Thurow C; Hering S; Baumann M; Krause M; Gurtner K Radiother Oncol; 2017 Sep; 124(3):496-503. PubMed ID: 28807520 [TBL] [Abstract][Full Text] [Related]
17. 111In-cetuximab-F(ab')2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model. van Dijk LK; Boerman OC; Franssen GM; Kaanders JH; Bussink J J Nucl Med; 2015 Feb; 56(2):287-92. PubMed ID: 25552666 [TBL] [Abstract][Full Text] [Related]
18. Dasatinib Inhibits DNA Repair after Radiotherapy Specifically in pSFK-Expressing Tumor Areas in Head and Neck Xenograft Tumors. Stegeman H; Span PN; Rijken PF; Cockx SC; Wheeler DL; Iida M; van der Kogel AJ; Kaanders JH; Bussink J Transl Oncol; 2013 Aug; 6(4):413-9. PubMed ID: 23908684 [TBL] [Abstract][Full Text] [Related]
19. Targeting of β1 integrins impairs DNA repair for radiosensitization of head and neck cancer cells. Dickreuter E; Eke I; Krause M; Borgmann K; van Vugt MA; Cordes N Oncogene; 2016 Mar; 35(11):1353-62. PubMed ID: 26073085 [TBL] [Abstract][Full Text] [Related]
20. Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives. Bauman JE; Duvvuri U; Thomas S; Gooding WE; Clump DA; Karlovits B; Wehbe A; Miller FR; Kim S; Sen M; Heron DE; Grandis JR; Argiris A Cancer; 2018 Oct; 124(19):3881-3889. PubMed ID: 30291796 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]